Virginia 2026 Regular Session

Virginia House Bill HB830

Introduced
1/13/26  
Refer
1/13/26  
Report Pass
2/5/26  
Report Pass
2/13/26  
Engrossed
2/16/26  
Refer
2/18/26  
Report Pass
3/2/26  
Report Pass
3/6/26  
Engrossed
3/10/26  
Engrossed
3/11/26  
Enrolled
3/30/26  
Chaptered
4/13/26  

Caption

An Act to amend and reenact ยงยง 38.2-3467 and 38.2-3470 of the Code of Virginia, relating to pharmacy benefits managers; requirements; application of law; report.

Impact

The bill is poised to impact the operation and regulatory landscape around pharmacy benefits in Virginia significantly. By mandating that PBMs reimburse pharmacies at rates equal to or greater than what they report to affiliated entities, it aims to create a more equitable framework within the pharmaceutical distribution chain. Additionally, the legislation includes provisions to prevent practices like spread pricing and mandates the use of pass-through pricing models, which could change how PBMs manage and reimburse pharmacy services.

Summary

House Bill 830 amends the Code of Virginia to establish new regulatory requirements for pharmacy benefits managers (PBMs) and carriers. It prohibits specific practices that PBMs can undertake, such as charging unjust fees to pharmacies and retaliating against them for exercising their rights. The bill aims to ensure that pharmacists are treated fairly under contracts with carriers, particularly regarding reimbursement amounts and the processing of claims.

Sentiment

General sentiment around HB830 has been supportive, as it seeks to mitigate ongoing concerns about PBM practices that negatively affect both pharmacists and patients. Legislators have expressed a strong desire to enhance transparency and accountability in the pharmacy reimbursement process. However, there may be some dissenters who argue that excessive regulations could potentially lead to unintended consequences, such as increased costs or reduced access to pharmacy services.

Contention

Key points of contention center around the implications for PBMs and whether the regulations may overly restrict their operations, possibly leading to reduced competition in the market. Critics of the bill may argue that it places a heavier burden on PBMs, potentially resulting in increases in drug costs passed onto consumers. The balance between regulating pharmacy benefits effectively while maintaining incentives for PBMs remains at the heart of the debate surrounding this legislation.

Companion Bills

No companion bills found.

Similar Bills

No similar bills found.